Skip to main content

Table 4 ApoE phenotype determined by mass spectrometry

From: Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer’s disease

Diagnosis

APOE ε2/ε3 (n)

APOE ε2/ε4 (n)

APOE ε3/ε3 (n)

APOE ε3/ε4 (n)

APOE ε4/ε4 (n)

Whole cohort (n = 125)

5

3

40

47

30

Controls (n = 39)

2

2

21

14

0

MCI-MCI (n = 30)

3

1

8

7

11

MCI-ADD (n = 28)

0

0

7

10

11

ADD (n = 28)

0

0

4

16

8

  1. MCI-MCI patients with amnestic mild cognitive impairment that did not progress to an ADD diagnosis, MCI-ADD patients with mild cognitive impairment that progressed to ADD diagnosis after two years, ADD Alzheimer’s disease with dementia patients diagnosed at baseline, APOE Apolipoprotein E gene